These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8957341)

  • 41. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.
    de Reijke T; Derobert E;
    Eur Urol; 2002 Aug; 42(2):139-46. PubMed ID: 12160584
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nilutamide-induced neutropenia.
    Eaton VS; Blackmore TK
    BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
    [No Abstract]   [Full Text] [Related]  

  • 43. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
    Navratil H
    Prog Clin Biol Res; 1987; 243A():401-10. PubMed ID: 3116551
    [No Abstract]   [Full Text] [Related]  

  • 45. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological and clinical studies of the antiandrogen Anandron.
    Moguilewsky M; Bertagna C; Hucher M
    J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
    Namer M; Amiel J; Toubol J
    Am J Clin Oncol; 1988; 11 Suppl 2():S191-6. PubMed ID: 3071952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen blockade and suppression for prostate carcinoma.
    Lancet; 1989 Oct; 2(8670):1020. PubMed ID: 2572747
    [No Abstract]   [Full Text] [Related]  

  • 49. [An unusual presentation of prostate cancer].
    Joual A; Rabii R; Aboutaeib R; el Moussaoui A; Benjelloun S
    Ann Urol (Paris); 1996; 30(5):262-3. PubMed ID: 8975593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
    Moguilewsky M; Cotard M; Proulx L; Tournemine C; Raynaud JP
    Prog Clin Biol Res; 1987; 243A():315-40. PubMed ID: 3116549
    [No Abstract]   [Full Text] [Related]  

  • 51. Antiandrogen withdrawal syndrome with nilutamide.
    Huan SD; Gerridzen RG; Yau JC; Stewart DJ
    Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-androgens in treatment of prostate cancer.
    Waxman J; Pandha H
    Lancet; 1995 Oct; 346(8981):1030. PubMed ID: 7475556
    [No Abstract]   [Full Text] [Related]  

  • 53. Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
    Pavone-Macaluso M
    Prog Clin Biol Res; 1991; 370():203-5. PubMed ID: 1924452
    [No Abstract]   [Full Text] [Related]  

  • 54. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 55. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
    Decensi A; Torrisi R; Fontana V
    Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Nilutamide-induced acute hepatitis].
    Hammel P; Ducreux M; Bismuth E; Ladouch-Badre A; Benoit G; Buffet C; Etienne JP
    Gastroenterol Clin Biol; 1991; 15(6-7):557. PubMed ID: 1916139
    [No Abstract]   [Full Text] [Related]  

  • 57. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
    Sciarra A; Cardi A; Di Silverio F
    Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.
    Pavone-Macaluso M; Cacciatore M; Daricello G; Pavone C; Serretta V
    Ann N Y Acad Sci; 1990; 595():328-33. PubMed ID: 2375611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.